Effects of type 1 diabetes mellitus on skeletal muscle: Clinical observations and physiological mechanisms

Pediatric Diabetes

Volumn 12, Issue 4 PART 1, 2011, Pages 345-364

  Krause, Matthew P ^a,b   Riddell, Michael C ^b   Hawke, Thomas J ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b YORK UNIVERSITY   (Canada)

Author keywords

Atrophy; Hormones; Impaired function; Muscle wasting; Myopathy

Indexed keywords

HYDROCORTISONE; INTERLEUKIN 6; LIPID; PLASMINOGEN ACTIVATOR INHIBITOR 1; SOMATOMEDIN C;

CLINICAL OBSERVATION; DIABETIC MYOPATHY; EXERCISE; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MUSCLE ATROPHY; MUSCLE CELL; MYOPATHY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SKELETAL MUSCLE; WORK;

ADOLESCENT; ADULT; AGED; ANIMALS; BLOOD GLUCOSE; CHILD; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; HYDROCORTISONE; HYPERGLYCEMIA; INSULIN-LIKE GROWTH FACTOR I; INTERLEUKIN-6; LIPID METABOLISM; MALE; MIDDLE AGED; MUSCLE CONTRACTION; MUSCLE FIBERS, SKELETAL; MUSCLE PROTEINS; MUSCLE, SKELETAL; MUSCULAR ATROPHY; OXYGEN CONSUMPTION; PLASMINOGEN ACTIVATOR INHIBITOR 1; REGENERATION; WORK CAPACITY EVALUATION;

EID: 78649502788     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/j.1399-5448.2010.00699.x     Document Type: Review

References (195)

1. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005: 54: 1615-1625.
2. Andersen H, Gadeberg PC, Brock B, Jakobsen J. Muscular atrophy in diabetic neuropathy: a stereological magnetic resonance imaging study. Diabetologia 1997: 40: 1062-1069.
3. Andersen H, Gjerstad MD, Jakobsen J. Atrophy of foot muscles: a measure of diabetic neuropathy. Diabetes Care 2004: 27: 2382-2385.
4. Andersen H, Poulsen PL, Mogensen CE, Jakobsen J. Isokinetic muscle strength in long-term IDDM patients in relation to diabetic complications. Diabetes 1996: 45: 440-445.
5. Andersen H, Schmitz O, Nielsen S. Decreased isometric muscle strength after acute hyperglycaemia in type 1 diabetic patients. Diabet Med 2005: 22: 1401-1407.
6. Hawke TJ, Garry DJ. Myogenic satellite cells: physiology to molecular biology. J Appl Physiol 2001: 91: 534-551.
7. Mozdziak PE, Pulvermacher PM, Schultz E. Unloading of juvenile muscle results in a reduced muscle size 9 wk after reloading. J Appl Physiol 2000: 88: 158-164.
8. Darr KC, Schultz E. Hindlimb suspension suppresses muscle growth and satellite cell proliferation. J Appl Physiol 1989: 67: 1827-1834.
9. Wanek LJ, Snow MH. Activity-induced fiber regeneration in rat soleus muscle. Anat Rec 2000: 258: 176-185.
10. Jakobsen J, Reske-Nielsen E. Diffuse muscle fiber atrophy in newly diagnosed diabetes. Clin Neuropathol 1986: 5: 73-77.
11. Reske-Nielsen E, Harmsen A, Vorre P. Ultrastructure of muscle biopsies in recent, short-term and long-term juvenile diabetes. Acta Neurol Scand 1977: 55: 345-362.
12. Crowther GJ, Milstein JM, Jubrias SA, Kushmerick MJ, Gronka RK, Conley KE. Altered energetic properties in skeletal muscle of men with well-controlled insulin-dependent (type 1) diabetes. Am J Physiol Endocrinol Metab 2003: 284: E655-E662.
13. Fritzsche K, Bluher M, Schering S, Buchwalow IB, Kern M, Linke A, Oberbach A, Adams V, Punkt K. Metabolic profile and nitric oxide synthase expression of skeletal muscle fibers are altered in patients with type 1 diabetes. Exp Clin Endocrinol Diabetes 2008: 116: 606-613.
14. Austin A, Warty V, Janosky J, Arslanian S. The relationship of physical fitness to lipid and lipoprotein(a) levels in adolescents with IDDM. Diabetes Care 1993: 16: 421-425.
15. Baraldi E, Monciotti C, Filippone M et al. Gas exchange during exercise in diabetic children. Pediatr Pulmonol 1992: 13: 155-160.
16. Gusso S, Hofman P, Lalande S, Cutfield W, Robinson E, Baldi JC. Impaired stroke volume and aerobic capacity in female adolescents with type 1 and type 2 diabetes mellitus. Diabetologia 2008: 51: 1317-1320.
17. Hagan RD, Marks JF, Warren PA. Physiologic responses of juvenile-onset diabetic boys to muscular work. Diabetes 1979: 28: 1114-1119.
18. Huttunen NP, Kaar ML, Knip M, Mustonen A, Puukka R, Akerblom HK. Physical fitness of children and adolescents with insulin-dependent diabetes mellitus. Ann Clin Res 1984: 16: 1-5.
19. Komatsu WR, Gabbay MA, Castro ML et al. Aerobic exercise capacity in normal adolescents and those with type 1 diabetes mellitus. Pediatr Diabetes 2005: 6: 145-149.
20. Larsson Y, Persson B, Sterky G, Thoren C. Functional adaptation to rigorous training and exercise in diabetic and nondiabetic adolescents. J Appl Physiol 1964: 19: 629-635.
21. Larsson YA, Sterky GC, Ekengren KE, Moller TG. Physical fitness and the influence of training in diabetic adolescent girls. Diabetes 1962: 11: 109-117.
22. Niranjan V, McBrayer DG, Ramirez LC, Raskin P, Hsia CC. Glycemic control and cardiopulmonary function in patients with insulin-dependent diabetes mellitus. Am J Med 1997: 103: 504-513.
23. Poortmans JR, Saerens P, Edelman R, Vertongen F, Dorchy H. Influence of the degree of metabolic control on physical fitness in type I diabetic adolescents. Int J Sports Med 1986: 7: 232-235.
24. Rowland TW, Martha PM Jr, Reiter EO, Cunningham LN. The influence of diabetes mellitus on cardiovascular function in children and adolescents. Int J Sports Med 1992: 13: 431-435.
25. Sterky G. Physical work capacity in diabetic schoolchildren. Acta Paediatr 1963: 52: 1-10.
26. Veves A, Saouaf R, Donaghue VM et al. Aerobic exercise capacity remains normal despite impaired endothelial function in the micro- and macrocirculation of physically active IDDM patients. Diabetes 1997: 46: 1846-1852.
27. Nugent AM, Steele IC, al-Modaris F et al. Exercise responses in patients with IDDM. Diabetes Care 1997: 20: 1814-1821.
28. Heyman E, Briard D, Gratas-Delamarche A, Delamarche P, De Kerdanet M. Normal physical working capacity in prepubertal children with type 1 diabetes compared with healthy controls. Acta Paediatr 2005: 94: 1389-1394.
29. Raile K, Kapellen T, Schweiger A et al. Physical activity and competitive sports in children and adolescents with type 1 diabetes. Diabetes Care 1999: 22: 1904-1905.
30. Massin MM, Lebrethon MC, Rocour D, Gerard P, Bourguignon JP. Patterns of physical activity determined by heart rate monitoring among diabetic children. Arch Dis Child 2005: 90: 1223-1226.
31. Sarnblad S, Ekelund U, Aman J. Physical activity and energy intake in adolescent girls with type 1 diabetes. Diabet Med 2005: 22: 893-899.
32. Moy CS, Songer TJ, LaPorte RE et al. Insulin-dependent diabetes mellitus, physical activity, and death. Am J Epidemiol 1993: 137: 74-81.
33. Valerio G, Spagnuolo MI, Lombardi F, Spadaro R, Siano M, Franzese A. Physical activity and sports participation in children and adolescents with type 1 diabetes mellitus. Nutr Metab Cardiovasc Dis 2007: 17: 376-382.
34. Andersen H. Muscular endurance in long-term IDDM patients. Diabetes Care 1998: 21: 604-609.
35. Almeida S, Riddell MC, Cafarelli E. Slower conduction velocity and motor unit discharge frequency are associated with muscle fatigue during isometric exercise in type 1 diabetes mellitus. Muscle Nerve 2008: 37: 231-240.
36. Reske-Nielsen E, Lundbaek K, Gregersen G, Harmsen A. Pathological changes in the central and peripheral nervous system of young long-term diabetics. the terminal neuro-muscular apparatus. Diabetologia 1970: 6: 98-103.
37. Andreassen CS, Jakobsen J, Ringgaard S, Ejskjaer N, Andersen H. Accelerated atrophy of lower leg and foot muscles-a follow-up study of long-term diabetic polyneuropathy using magnetic resonance imaging (MRI). Diabetologia 2009: 52: 1182-1191.
38. Reske-Nielsen E, Gregersen G, Harmsen A, Lundbaek K. Morphological abnormalities of the terminal neuromuscular apparatus in recent juvenile diabetes. Diabetologia 1970: 6: 104-109.
39. Baum VC, Levitsky LL, Englander RM. Abnormal cardiac function after exercise in insulin-dependent diabetic children and adolescents. Diabetes Care 1987: 10: 319-323.
40. Friedman NE, Levitsky LL, Edidin DV, Vitullo DA, Lacina SJ, Chiemmongkoltip P. Echocardiographic evidence for impaired myocardial performance in children with type I diabetes mellitus. Am J Med 1982: 73: 846-850.
41. Riggs TW, Transue D. Doppler echocardiographic evaluation of left ventricular diastolic function in adolescents with diabetes mellitus. Am J Cardiol 1990: 65: 899-902.
42. Andreassen CS, Jakobsen J, Flyvbjerg A, Andersen H. Expression of neurotrophic factors in diabetic muscle-relation to neuropathy and muscle strength. Brain 2009: 132: 2724-2733.
43. McKewen MW, Rehrer NJ, Cox C, Mann J. Glycaemic control, muscle glycogen and exercise performance in IDDM athletes on diets of varying carbohydrate content. Int J Sports Med 1999: 20: 349-353.
44. Riddell MC, Bar-Or O, Gerstein HC, Heigenhauser GJ. Perceived exertion with glucose ingestion in adolescent males with IDDM. Med Sci Sports Exerc 2000: 32: 167-173.
45. Muoio DM, Newgard CB. Mechanisms of disease: molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes. Nat Rev Mol Cell Biol 2008: 9: 193-205.
46. Watt MJ. Storing up trouble: does accumulation of intramyocellular triglyceride protect skeletal muscle from insulin resistance? Clin Exp Pharmacol Physiol 2009: 36: 5-11.
47. Kraegen EW, Saha AK, Preston E et al. Increased malonyl-CoA and diacylglycerol content and reduced AMPK activity accompany insulin resistance induced by glucose infusion in muscle and liver of rats. Am J Physiol Endocrinol Metab 2006: 290: E471-E479.
48. Kraegen EW, Cooney GJ. Free fatty acids and skeletal muscle insulin resistance. Curr Opin Lipidol 2008: 19: 235-241.
49. Bernroider E, Brehm A, Krssak M et al. The role of intramyocellular lipids during hypoglycemia in patients with intensively treated type 1 diabetes. J Clin Endocrinol Metab 2005: 90: 5559-5565.
50. Perseghin G, Lattuada G, Danna M et al. Insulin resistance, intramyocellular lipid content, and plasma adiponectin in patients with type 1 diabetes. Am J Physiol Endocrinol Metab 2003: 285: E1174-E1181.
51. Dube MC, Joanisse DR, Prud'homme D et al. Muscle adiposity and body fat distribution in type 1 and type 2 diabetes: varying relationships according to diabetes type. Int J Obes (Lond) 2006: 30: 1721-1728.
52. Standl E, Lotz N, Dexel T, Janka HU, Kolb HJ. Muscle triglycerides in diabetic subjects. Effect of insulin deficiency and exercise. Diabetologia 1980: 18: 463-469.
53. Ebeling P, Essen-Gustavsson B, Tuominen JA, Koivisto VA. Intramuscular triglyceride content is increased in IDDM. Diabetologia 1998: 41: 111-115.
54. Muoio DM. Intramuscular triacylglycerol and insulin resistance: guilty as charged or wrongly accused? Biochim Biophys Acta 2009.
55. Coen PM, Dube JJ, Amati F et al. Insulin resistance is associated with higher intramyocellular triglycerides in type I but not type II myocytes concomitant with higher ceramide content. Diabetes 2010: 59: 80-88.
56. Ling AH, Donaghue KC, Howard NJ et al. Intramyocellular lipid, adiposity, and muscle oxygen supply in prepubertal type 1 diabetes. Pediatr Diabetes 2003: 4: 126-131.
57. Galler A, Gelbrich G, Kratzsch J, Noack N, Kapellen T, Kiess W. Elevated serum levels of adiponectin in children, adolescents and young adults with type 1 diabetes and the impact of age, gender, body mass index and metabolic control: a longitudinal study. Eur J Endocrinol 2007: 157: 481-489.
58. Kiess W, Anil M, Blum WF et al. Serum leptin levels in children and adolescents with insulin-dependent diabetes mellitus in relation to metabolic control and body mass index. Eur J Endocrinol 1998: 138: 501-509.
59. Chan O, Inouye K, Riddell MC, Vranic M, Matthews SG. Diabetes and the hypothalamo-pituitary-adrenal (HPA) axis. Minerva Endocrinol 2003: 28: 87-102.
60. Roy M, Collier B, Roy A. Hypothalamic-pituitary-adrenal axis dysregulation among diabetic outpatients. Psychiatry Res 1990: 31: 31-37.
61. Galassetti PR, Iwanaga K, Crisostomo M, Zaldivar FP, Larson J, Pescatello A. Inflammatory cytokine, growth factor and counterregulatory responses to exercise in children with type 1 diabetes and healthy controls. Pediatr Diabetes 2006: 7: 16-24.
62. Sills IN, Cerny FJ. Responses to continuous and intermittent exercise in healthy and insulin-dependent diabetic children. Med Sci Sports Exerc 1983: 15: 450-454.
63. Diabetes Research in Children Network (DirecNet) Study Group, Tsalikian E, Tamborlane W et al. Blunted counterregulatory hormone responses to hypoglycemia in young children and adolescents with well-controlled type 1 diabetes. Diabetes Care 2009: 32: 1954-1959.
64. Bosnyak Z, Forrest KY, Maser RE, Becker D, Orchard TJ, Pittsburgh Epidemiology of Diabetes Complications Study. Do plasminogen activator inhibitor (PAI-1) or tissue plasminogen activator PAI-1 complexes predict complications in type 1 diabetes: the Pittsburgh epidemiology of diabetes complications study. Diabet Med 2003: 20: 147-151.
65. Chen LL, Zhang JY, Wang BP. Renoprotective effects of fenofibrate in diabetic rats are achieved by suppressing kidney plasminogen activator inhibitor-1. Vascul Pharmacol 2006: 44: 309-315.
66. De Taeye B, Smith LH, Vaughan DE. Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease. Curr Opin Pharmacol 2005: 5: 149-154.
67. Gruden G, Cavallo-Perin P, Bazzan M, Stella S, Vuolo A, Pagano G. PAI-1 and factor VII activity are higher in IDDM patients with microalbuminuria. Diabetes 1994: 43: 426-429.
68. Small M, Kluft C, MacCuish AC, Lowe GD. Tissue plasminogen activator inhibition in diabetes mellitus. Diabetes Care 1989: 12: 655-658.
69. Koh TJ, Bryer SC, Pucci AM, Sisson TH. Mice deficient in plasminogen activator inhibitor-1 have improved skeletal muscle regeneration. Am J Physiol Cell Physiol 2005: 289: C217-C223.
70. Zeitler P, Thiede A, Muller HL. Prospective study on plasma clotting parameters in diabetic children-no evidence for specific changes in coagulation system. Exp Clin Endocrinol Diabetes 2001: 109: 146-150.
71. Barton BE. IL-6-like cytokines and cancer cachexia: consequences of chronic inflammation. Immunol Res 2001: 23: 41-58.
72. Jensen GL. Inflammation: roles in aging and sarcopenia. J Parenter Enteral Nutr 2008: 32: 656-659.
73. Dogan Y, Akarsu S, Ustundag B, Yilmaz E, Gurgoze MK. Serum IL-1beta, IL-2, and IL-6 in insulin-dependent diabetic children. Mediators Inflamm 2006: 2006: 59206.
74. Galassetti P, Larson J, Iwanaga K, Salsberg SL, Eliakim A, Pontello A. Effect of a high-fat meal on the growth hormone response to exercise in children. J Pediatr Endocrinol Metab 2006: 19: 777-786.
75. Rosa JS, Flores RL, Oliver SR, Pontello AM, Zaldivar FP Jr, Galassetti PR. Resting and exercise-induced IL-6 levels in children with type 1 diabetes reflect hyperglycemic profiles during the previous 3 days. J Appl Physiol 2009.
76. Rosa JS, Oliver SR, Mitsuhashi M et al. Altered kinetics of interleukin-6 and other inflammatory mediators during exercise in children with type 1 diabetes. J Investig Med 2008: 56: 701-713.
77. Gordin D, Forsblom C, Ronnback M et al. Acute hyperglycaemia induces an inflammatory response in young patients with type 1 diabetes. Ann Med 2008: 40: 627-633.
78. Haddad F, Zaldivar F, Cooper DM, Adams GR. IL-6-induced skeletal muscle atrophy. J Appl Physiol 2005: 98: 911-917.
79. Fischer CP. Interleukin-6 in acute exercise and training: what is the biological relevance? Exerc Immunol Rev 2006: 12: 6-33.
80. Barton ER. Viral expression of insulin-like growth factor-I isoforms promotes different responses in skeletal muscle. J Appl Physiol 2006: 100: 1778-1784.
81. Booth F. The many flavors of IGF-I. J Appl Physiol 2006: 100: 1755-1756.
82. Clemmons DR, Underwood LE. Role of insulin-like growth factors and growth hormone in reversing catabolic states. Horm Res 1992: 38 (Suppl. 2): 37-40.
83. Grounds MD. Reasons for the degeneration of ageing skeletal muscle: a central role for IGF-1 signalling. Biogerontology 2002: 3: 19-24.
84. Moyer-Mileur LJ, Slater H, Jordan KC, Murray MA. IGF-1 and IGF-binding proteins and bone mass, geometry, and strength: relation to metabolic control in adolescent girls with type 1 diabetes. J Bone Miner Res 2008: 23: 1884-1891.
85. Wedrychowicz A, Dziatkowiak H, Nazim J, Sztefko K. Insulin-like growth factor-1 and its binding proteins, IGFBP-1 and IGFBP-3, in adolescents with type-1 diabetes mellitus and microalbuminuria. Horm Res 2005: 63: 245-251.
86. Jehle PM, Jehle DR, Mohan S, Bohm BO. Serum levels of insulin-like growth factor system components and relationship to bone metabolism in type 1 and type 2 diabetes mellitus patients. J Endocrinol 1998: 159: 297-306.
87. Adams GR, Haddad F. The relationships among IGF-1, DNA content, and protein accumulation during skeletal muscle hypertrophy. J Appl Physiol 1996: 81: 2509-2516.
88. Adams GR. Invited review: autocrine/paracrine IGF-I and skeletal muscle adaptation. J Appl Physiol 2002: 93: 1159-1167.
89. Fahim MA, el-Sabban F, Davidson N. Muscle contractility decrement and correlated morphology during the pathogenesis of streptozotocin-diabetic mice. Anat Rec 1998: 251: 240-244.
90. Lesniewski LA, Miller TA, Armstrong RB. Mechanisms of force loss in diabetic mouse skeletal muscle. Muscle Nerve 2003: 28: 493-500.
91. Sanchez OA, Snow LM, Lowe DA, Serfass RC, Thompson LV. Effects of endurance exercise-training on single-fiber contractile properties of insulin-treated streptozotocin-induced diabetic rats. J Appl Physiol 2005: 99: 472-478.
92. Vignaud A, Ramond F, Hourde C, Keller A, Butler-Browne G, Ferry A. Diabetes provides an unfavorable environment for muscle mass and function after muscle injury in mice. Pathobiology 2007: 74: 291-300.
93. Cameron NE, Cotter MA, Robertson S. Changes in skeletal muscle contractile properties in streptozocin-induced diabetic rats and role of polyol pathway and hypoinsulinemia. Diabetes 1990: 39: 460-465.
94. Cotter M, Cameron NE, Lean DR, Robertson S. Effects of long-term streptozotocin diabetes on the contractile and histochemical properties of rat muscles. Q J Exp Physiol 1989: 74: 65-74.
95. Cotter MA, Cameron NE, Robertson S, Ewing I. Polyol pathway-related skeletal muscle contractile and morphological abnormalities in diabetic rats. Exp Physiol 1993: 78: 139-155.
96. McGuire M, MacDermott M. The influence of streptozotocin diabetes and metformin on erythrocyte volume and on the membrane potential and the contractile characteristics of the extensor digitorum longus and soleus muscles in rats. Exp Physiol 1999: 84: 1051-1058.
97. Stephenson GM, O'Callaghan A, Stephenson DG. Single-fiber study of contractile and biochemical properties of skeletal muscles in streptozotocin-induced diabetic rats. Diabetes 1994: 43: 622-628.
98. Paulus SF, Grossie J. Skeletal muscle in alloxan diabetes. A comparison of isometric contractions in fast and slow muscle. Diabetes 1983: 32: 1035-1039.
99. Ganguly PK, Mathur S, Gupta MP, Beamish RE, Dhalla NS. Calcium pump activity of sarcoplasmic reticulum in diabetic rat skeletal muscle. Am J Physiol 1986: 251: E515-E523.
100. McGuire M, Dumbleton M, MacDermott M, Bradford A. Contractile and electrical properties of sternohyoid muscle in streptozotocin diabetic rats. Clin Exp Pharmacol Physiol 2001: 28: 184-187.
101. Krause MP, Riddell MC, Gordon CS, Imam SA, Cafarelli E, Hawke TJ. Diabetic myopathy differs between Ins2Akita+/- and streptozotocin-induced type 1 diabetic models. J Appl Physiol 2009: 106: 1650-1659.
102. Parker KC, Kong SW, Walsh RJ et al. Fast-twitch sarcomeric and glycolytic enzyme protein loss in inclusion body myositis. Muscle Nerve 2009: 39: 739-753.
103. Serrano AL, Jardi M, Suelves M, Klotman PE, Munoz-Canoves P. HIV-1 transgenic expression in mice induces selective atrophy of fast-glycolytic skeletal muscle fibers. Front Biosci 2008: 13: 2797-2805.
104. Yu Z, Li P, Zhang M, Hannink M, Stamler JS, Yan Z. Fiber type-specific nitric oxide protects oxidative myofibers against cachectic stimuli. PLoS One 2008: 3: e2086.
105. Hasan MY, Alshuaib WB, Fahim MA. The impact of vitamin C on diabetes induced alterations at murine neuromuscular junction. Endocr Res 2002: 28: 49-59.
106. Armstrong RB, Gollnick PD, Ianuzzo CD. Histochemical properties of skeletal muscle fibers in streptozotocin-diabetic rats. Cell Tissue Res 1975: 162: 387-394.
107. Armstrong RB, Ianuzzo CD. Compensatory hypertrophy of skeletal muscle fibers in streptozotocin-diabetic rats. Cell Tissue Res 1977: 181: 255-266.
108. Klueber KM, Feczko JD. Ultrastructural, histochemical, and morphometric analysis of skeletal muscle in a murine model of type I diabetes. Anat Rec 1994: 239: 18-34.
109. Snow LM, Sanchez OA, McLoon LK, Serfass RC, Thompson LV. Myosin heavy chain isoform immunolabelling in diabetic rats with peripheral neuropathy. Acta Histochem 2005: 107: 221-229.
110. Medina-Sanchez M, Rodriguez-Sanchez C, Vega-Alvarez JA, Menedez-Pelaez A, Perez-Casas A. Proximal skeletal muscle alterations in streptozotocin-diabetic rats: a histochemical and morphometric analysis. Am J Anat 1991: 191: 48-56.
111. Schiaffino S, Reggiani C. Myosin isoforms in mammalian skeletal muscle. J Appl Physiol 1994: 77: 493-501.
112. Chao TT, Ianuzzo CD, Armstrong RB, Albright JT, Anapolle SE. Ultrastructural alterations in skeletal muscle fibers of streptozotocin-diabetic rats. Cell Tissue Res 1976: 168: 239-246.
113. Hong EG, Jung DY, Ko HJ et al. Nonobese, insulin-deficient Ins2Akita mice develop type 2 diabetes phenotypes including insulin resistance and cardiac remodeling. Am J Physiol Endocrinol Metab 2007: 293: E1687-E1696.
114. Noble EG, Ianuzzo CD. Influence of training on skeletal muscle enzymatic adaptations in normal and diabetic rats. Am J Physiol 1985: 249: E360-E365.
115. Fewell JG, Moerland TS. Responses of mouse fast and slow skeletal muscle to streptozotocin diabetes: myosin isoenzymes and phosphorous metabolites. Mol Cell Biochem 1995: 148: 147-154.
116. Chen V, Ianuzzo CD. Dosage effect of streptozotocin on rat tissue enzyme activities and glycogen concentration. Can J Physiol Pharmacol 1982: 60: 1251-1256.
117. Harmer AR, Chisholm DJ, McKenna MJ et al. Sprint training increases muscle oxidative metabolism during high-intensity exercise in patients with type 1 diabetes. Diabetes Care 2008: 31: 2097-2102.
118. Bonen A, Benton CR, Campbell SE et al. Plasmalemmal fatty acid transport is regulated in heart and skeletal muscle by contraction, insulin and leptin, and in obesity and diabetes. Acta Physiol Scand 2003: 178: 347-356.
119. Chen M, Yang YK, Loux TJ, Georgeson KE, Harmon CM. The role of hyperglycemia in FAT/CD36 expression and function. Pediatr Surg Int 2006: 22: 647-654.
120. Luiken JJ, Arumugam Y, Bell RC et al. Changes in fatty acid transport and transporters are related to the severity of insulin deficiency. Am J Physiol Endocrinol Metab 2002: 283: E612-E621.
121. Karakelides H, Asmann YW, Bigelow ML et al. Effect of insulin deprivation on muscle mitochondrial ATP production and gene transcript levels in type 1 diabetic subjects. Diabetes 2007: 56: 2683-2689.
122. Havel PJ, Hahn TM, Sindelar DK et al. Effects of streptozotocin-induced diabetes and insulin treatment on the hypothalamic melanocortin system and muscle uncoupling protein 3 expression in rats. Diabetes 2000: 49: 244-252.
123. Snow LM, Lynner CB, Nielsen EM, Neu HS, Thompson LV. Advanced glycation end product in diabetic rat skeletal muscle in vivo. Pathobiology 2006: 73: 244-251.
124. Snow LM, Fugere NA, Thompson LV. Advanced glycation end-product accumulation and associated protein modification in type II skeletal muscle with aging. J Gerontol A Biol Sci Med Sci 2007: 62: 1204-1210.
125. Alt N, Carson JA, Alderson NL et al. Chemical modification of muscle protein in diabetes. Arch Biochem Biophys 2004: 425: 200-206.
126. Ramamurthy B, Hook P, Jones AD, Larsson L. Changes in myosin structure and function in response to glycation. FASEB J 2001: 15: 2415-2422.
127. Ghahary A, Chakrabarti S, Sima AA, Murphy LJ. Effect of insulin and statil on aldose reductase expression in diabetic rats. Diabetes 1991: 40: 1391-1396.
128. Cameron NE, Cotter MA, Basso M, Hohman TC. Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats. Diabetologia 1997: 40: 271-281.
129. Giannoukakis N. Ranirestat as a therapeutic aldose reductase inhibitor for diabetic complications. Expert Opin Investig Drugs 2008: 17: 575-581.
130. Ramirez MA, Borja NL. Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy. Pharmacotherapy 2008: 28: 646-655.
131. Aragno M, Mastrocola R, Catalano MG, Brignardello E, Danni O, Boccuzzi G. Oxidative stress impairs skeletal muscle repair in diabetic rats. Diabetes 2004: 53: 1082-1088.
132. Mastrocola R, Reffo P, Penna F et al. Muscle wasting in diabetic and in tumor-bearing rats: role of oxidative stress. Free Radic Biol Med 2008: 44: 584-593.
133. Russell ST, Rajani S, Dhadda RS, Tisdale MJ. Mechanism of induction of muscle protein loss by hyperglycaemia. Exp Cell Res 2009: 315: 16-25.
134. Anderson EJ, Neufer PD. Type II skeletal myofibers possess unique properties that potentiate mitochondrial H(2)O(2) generation. Am J Physiol Cell Physiol 2006: 290: C844-C851.
135. Johnston AP, Campbell JE, Found JG, Riddell MC, Hawke TJ. Streptozotocin induces G2 arrest in skeletal muscle myoblasts and impairs muscle growth in vivo. Am J Physiol Cell Physiol 2007: 292: C1033-C1040.
136. Cross DA, Watt PW, Shaw M et al. Insulin activates protein kinase B, inhibits glycogen synthase kinase-3 and activates glycogen synthase by rapamycin-insensitive pathways in skeletal muscle and adipose tissue. FEBS Lett 1997: 406: 211-215.
137. Marzban L, Bhanot S, McNeill JH. In vivo effects of insulin and bis(maltolato)oxovanadium (IV) on PKB activity in the skeletal muscle and liver of diabetic rats. Mol Cell Biochem 2001: 223: 147-157.
138. Somwar R, Sumitani S, Taha C, Sweeney G, Klip A. Temporal activation of p70 S6 kinase and Akt1 by insulin: PI 3-kinase-dependent and -independent mechanisms. Am J Physiol 1998: 275: E618-E625.
139. Shen WH, Boyle DW, Wisniowski P, Bade A, Liechty EA. Insulin and IGF-I stimulate the formation of the eukaryotic initiation factor 4F complex and protein synthesis in C2C12 myotubes independent of availability of external amino acids. J Endocrinol 2005: 185: 275-289.
140. Hajduch E, Alessi DR, Hemmings BA, Hundal HS. Constitutive activation of protein kinase B alpha by membrane targeting promotes glucose and system A amino acid transport, protein synthesis, and inactivation of glycogen synthase kinase 3 in L6 muscle cells. Diabetes 1998: 47: 1006-1013.
141. Pain VM, Garlick PJ. Effect of streptozotocin diabetes and insulin treatment on the rate of protein synthesis in tissues of the rat in vivo. J Biol Chem 1974: 249: 4510-4514.
142. Pain VM, Albertse EC, Garlick PJ. Protein metabolism in skeletal muscle, diaphragm, and heart of diabetic rats. Am J Physiol 1983: 245: E604-E610.
143. Nair KS, Ford GC, Ekberg K, Fernqvist-Forbes E, Wahren J. Protein dynamics in whole body and in splanchnic and leg tissues in type I diabetic patients. J Clin Invest 1995: 95: 2926-2937.
144. Chow LS, Albright RC, Bigelow ML, Toffolo G, Cobelli C, Nair KS. Mechanism of insulin's anabolic effect on muscle: measurements of muscle protein synthesis and breakdown using aminoacyl-tRNA and other surrogate measures. Am J Physiol Endocrinol Metab 2006: 291: E729-E736.
145. Charlton MR, Balagopal P, Nair KS. Skeletal muscle myosin heavy chain synthesis in type 1 diabetes. Diabetes 1997: 46: 1336-1340.
146. Bennet WM, Connacher AA, Smith K, Jung RT, Rennie MJ. Inability to stimulate skeletal muscle or whole body protein synthesis in type 1 (insulin-dependent) diabetic patients by insulin-plus-glucose during amino acid infusion: studies of incorporation and turnover of tracer L-[1-13C]leucine. Diabetologia 1990: 33: 43-51.
147. Godil MA, Wilson TA, Garlick PJ, McNurlan MA. Effect of insulin with concurrent amino acid infusion on protein metabolism in rapidly growing pubertal children with type 1 diabetes. Pediatr Res 2005: 58: 229-234.
148. Charlton M, Nair KS. Protein metabolism in insulin-dependent diabetes mellitus. J Nutr 1998: 128: 323S-327S.
149. Lee SW, Dai G, Hu Z, Wang X, Du J, Mitch WE. Regulation of muscle protein degradation: coordinated control of apoptotic and ubiquitin-proteasome systems by phosphatidylinositol 3 kinase. J Am Soc Nephrol 2004: 15: 1537-1545.
150. Price SR, Bailey JL, Wang X et al. Muscle wasting in insulinopenic rats results from activation of the ATP-dependent, ubiquitin-proteasome proteolytic pathway by a mechanism including gene transcription. J Clin Invest 1996: 98: 1703-1708.
151. Lecker SH, Solomon V, Price SR, Kwon YT, Mitch WE, Goldberg AL. Ubiquitin conjugation by the N-end rule pathway and mRNAs for its components increase in muscles of diabetic rats. J Clin Invest 1999: 104: 1411-1420.
152. Lecker SH, Jagoe RT, Gilbert A et al. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J 2004: 18: 39-51.
153. Mitch WE, Bailey JL, Wang X, Jurkovitz C, Newby D, Price SR. Evaluation of signals activating ubiquitin-proteasome proteolysis in a model of muscle wasting. Am J Physiol 1999: 276: C1132-C1138.
154. Flaim KE, Copenhaver ME, Jefferson LS. Effects of diabetes on protein synthesis in fast- and slow-twitch rat skeletal muscle. Am J Physiol 1980: 239: E88-E95.
155. Medina-Sanchez M, Barneo-Serra L, Menendez-Pelaez A, Martinez-Esteban M. Effect of streptozotocin-induced diabetes and islet transplantation in proximal skeletal muscle: a histochemical and morphometric analysis. J Lab Clin Med 1994: 123: 921-929.
156. Datta SR, Dudek H, Tao X et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997: 91: 231-241.
157. Galetic I, Andjelkovic M, Meier R, Brodbeck D, Park J, Hemmings BA. Mechanism of protein kinase B activation by insulin/insulin-like growth factor-1 revealed by specific inhibitors of phosphoinositide 3-kinase-significance for diabetes and cancer. Pharmacol Ther 1999: 82: 409-425.
158. Ekladous D, Mehdi MZ, Costa M, Srivastava AK, Chiasson JL, Coderre L. Tissue- and fibre-specific modifications of insulin-signalling molecules in cardiac and skeletal muscle of diabetic rats. Clin Exp Pharmacol Physiol 2008: 35: 971-978.
159. Oku A, Nawano M, Ueta K et al. Inhibitory effect of hyperglycemia on insulin-induced Akt/protein kinase B activation in skeletal muscle. Am J Physiol Endocrinol Metab 2001: 280: E816-E824.
160. Frier BC, Noble EG, Locke M. Diabetes-induced atrophy is associated with a muscle-specific alteration in NF-kappaB activation and expression. Cell Stress Chaperones 2008: 13: 287-296.
161. Cai D, Frantz JD, Tawa NE Jr et al. IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell 2004: 119: 285-298.
162. Dehoux M, Van Beneden R, Pasko N et al. Role of the insulin-like growth factor I decline in the induction of atrogin-1/MAFbx during fasting and diabetes. Endocrinology 2004: 145: 4806-4812.
163. Binz K, Zapf J, Froesch ER. The role of insulin-like growth factor I in growth of diabetic rats. Acta Endocrinol (Copenh) 1989: 121: 628-632.
164. Scheiwiller E, Guler HP, Merryweather J et al. Growth restoration of insulin-deficient diabetic rats by recombinant human insulin-like growth factor I. Nature 1986: 323: 169-171.
165. Farrell PA, Fedele MJ, Hernandez J et al. Hypertrophy of skeletal muscle in diabetic rats in response to chronic resistance exercise. J Appl Physiol 1999: 87: 1075-1082.
166. Farrell PA, Fedele MJ, Vary TC, Kimball SR, Lang CH, Jefferson LS. Regulation of protein synthesis after acute resistance exercise in diabetic rats. Am J Physiol 1999: 276: E721-E727.
167. Fedele MJ, Lang CH, Farrell PA. Immunization against IGF-I prevents increases in protein synthesis in diabetic rats after resistance exercise. Am J Physiol Endocrinol Metab 2001: 280: E877-E885.
168. Oishi K, Ohkura N, Kasamatsu M et al. Tissue-specific augmentation of circadian PAI-1 expression in mice with streptozotocin-induced diabetes. Thromb Res 2004: 114: 129-135.
169. Oishi K, Ohkura N, Ishida N. Adrenal gland-dependent augmentation of plasminogen activator inhibitor-1 expression in streptozotocin-induced diabetic mice. J Thromb Haemost 2006: 4: 1566-1574.
170. Chan O, Inouye K, Akirav EM et al. Hyperglycemia does not increase basal hypothalamo-pituitary-adrenal activity in diabetes but it does impair the HPA response to insulin-induced hypoglycemia. Am J Physiol Regul Integr Comp Physiol 2005: 289: R235-R246.
171. Chen Y, Cao L, Ye J, Zhu D. Upregulation of myostatin gene expression in streptozotocin-induced type 1 diabetes mice is attenuated by insulin. Biochem Biophys Res Commun 2009: 388: 112-116.
172. Wieteska-Skrzeczynska W, Grzelkowska-Kowalczyk K, Jank M, Maciejewski H. Transcriptional dysregulation of skeletal muscle protein metabolism in streptozotocin-diabetic mice. J Physiol Pharmacol 2009: 60 (Suppl. 1): 29-36.
173. Ma K, Mallidis C, Bhasin S et al. Glucocorticoid-induced skeletal muscle atrophy is associated with upregulation of myostatin gene expression. Am J Physiol Endocrinol Metab 2003: 285: E363-E371.
174. De Benedetti F, Alonzi T, Moretta A et al. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J Clin Invest 1997: 99: 643-650.
175. De Benedetti F, Meazza C, Oliveri M et al. Effect of IL-6 on IGF binding protein-3: a study in IL-6 transgenic mice and in patients with systemic juvenile idiopathic arthritis. Endocrinology 2001: 142: 4818-4826.
176. Visser M, Pahor M, Taaffe DR et al. Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: the health ABC study. J Gerontol A Biol Sci Med Sci 2002: 57: M326-M332.
177. Goodman MN. Interleukin-6 induces skeletal muscle protein breakdown in rats. Proc Soc Exp Biol Med 1994: 205: 182-185.
178. Galassetti PR, Iwanaga K, Pontello AM, Zaldivar FP, Flores RL, Larson JK. Effect of prior hyperglycemia on IL-6 responses to exercise in children with type 1 diabetes. Am J Physiol Endocrinol Metab 2006: 290: E833-E839.
179. Kanemaki T, Kitade H, Kaibori M et al. Interleukin 1beta and interleukin 6, but not tumor necrosis factor alpha, inhibit insulin-stimulated glycogen synthesis in rat hepatocytes. Hepatology 1998: 27: 1296-1303.
180. Gulati AK, Swamy MS. Regeneration of skeletal muscle in streptozotocin-induced diabetic rats. Anat Rec 1991: 229: 298-304.
181. Copray S, Liem R, Brouwer N, Greenhaff P, Habens F, Fernyhough P. Contraction-induced muscle fiber damage is increased in soleus muscle of streptozotocin-diabetic rats and is associated with elevated expression of brain-derived neurotrophic factor mRNA in muscle fibers and activated satellite cells. Exp Neurol 2000: 161: 597-608.
182. Suelves M, Vidal B, Ruiz V et al. The plasminogen activation system in skeletal muscle regeneration: Antagonistic roles of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1). Front Biosci 2005: 10: 2978-2985.
183. Fibbi G, Barletta E, Dini G et al. Cell invasion is affected by differential expression of the urokinase plasminogen activator/urokinase plasminogen activator receptor system in muscle satellite cells from normal and dystrophic patients. Lab Invest 2001: 81: 27-39.
184. Fibbi G, D'Alessio S, Pucci M, Cerletti M, Del Rosso M. Growth factor-dependent proliferation and invasion of muscle satellite cells require the cell-associated fibrinolytic system. Biol Chem 2002: 383: 127-136.
185. van Zonneveld AJ, Curriden SA, Loskutoff DJ. Type 1 plasminogen activator inhibitor gene: functional analysis and glucocorticoid regulation of its promoter. Proc Natl Acad Sci U S A 1988: 85: 5525-5529.
186. Brannon MA, Dodson MV, Wheeler BA, Mathison BD, Mathison BA. Satellite cells derived from streptozotocin-diabetic rats display altered fusion parameters in vitro. Metabolism 1989: 38: 348-352.
187. Souayah N, Potian JG, Garcia CC et al. Motor unit number estimate as a predictor of motor dysfunction in an animal model of type 1 diabetes. Am J Physiol Endocrinol Metab 2009: 297: E602-E608.
188. Bobinac D, Malnar-Dragojevic D, Bajek S, Soic-Vranic T, Jerkovic R. Muscle fiber type composition and morphometric properties of denervated rat extensor digitorum longus muscle. Croat Med J 2000: 41: 294-297.
189. Ohira Y, Yoshinaga T, Ohara M et al. The role of neural and mechanical influences in maintaining normal fast and slow muscle properties. Cells Tissues Organs 2006: 182: 129-142.
190. Niederle B, Mayr R. Course of denervation atrophy in type I and type II fibres of rat extensor digitorum longus muscle. Anat Embryol (Berl) 1978: 153: 9-21.
191. Chokroverty S, Reyes MG, Rubino FA, Tonaki H. The syndrome of diabetic amyotrophy. Ann Neurol 1977: 2: 181-194.
192. Taylor BV, Dunne JW. Diabetic amyotrophy progressing to severe quadriparesis. Muscle Nerve 2004: 30: 505-509.
193. Kapur S, Brunet JA, McKendry RJ. Diabetic muscle infarction: case report and review. J Rheumatol 2004: 31: 190-194.
194. Trujillo-Santos AJ. Diabetic muscle infarction: an underdiagnosed complication of long-standing diabetes. Diabetes Care 2003: 26: 211-215.
195. Robertson K, Adolfsson P, Scheiner G, Hanas R, Riddell MC. Exercise in children and adolescents with diabetes. Pediatr Diabetes 2009: 10 (Suppl. 12): 154-168.